B. Riley Securities Downgrades Longboard Pharmaceuticals to Neutral, Raises Price Target to $60

Benzinga · 10/14 17:18
B. Riley Securities analyst Kalpit Patel downgrades Longboard Pharmaceuticals (NASDAQ:LBPH) from Buy to Neutral and raises the price target from $45 to $60.